<p>關注 <strong>Eupraxia Pharmaceuticals Inc.</strong> (TSE:EPRX) 的人無疑會對公司獨立董事 Joseph Freedman 最近購買股票的消息感到好奇，他以平均每股 CA$7.64 的價格花費了高達 CA$1.8 百萬購買股票。這不僅是一個巨大的舉動，還使他們的持股增加了 13%，這無疑是令人欣慰的。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<h2>Eupraxia Pharmaceuticals 最近 12 個月的內部交易</h2>
<p>事實上，根據我們的記錄，Joseph Freedman 最近的購買是過去 12 個月內內部人士對 Eupraxia Pharmaceuticals 股票的最大購買。因此，很明顯，有內部人士希望在當前價格（CA$7.99 左右）附近進行購買。當然，他們可能改變了主意。但這表明他們持樂觀態度。我們總是喜歡看到內部人士的購買，但值得注意的是，如果這些購買是在遠低於今天的股價時進行的，因為隨着價格上漲，價值折扣可能已經縮小。令人欣慰的是，Eupraxia Pharmaceuticals 的內部人士決定在接近當前價格時購買股票。</p>
<p>雖然 Eupraxia Pharmaceuticals 的內部人士在過去一年中購買了股票，但他們並沒有出售。您可以在下面的圖表中看到過去一年內（公司和個人）的內部交易。如果您想確切知道是誰出售的、出售了多少以及何時出售，只需點擊下面的圖表！</p>
<p>查看我們對 Eupraxia Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331"/></p>
<p>TSX:EPRX 內部交易量 2025 年 9 月 28 日</p>
<p>還有很多其他公司也有內部人士購買股票。您可能不想錯過這份 <strong>免費</strong> 的被低估小型公司的名單，內部人士正在購買。</p>
<h2>內部持股</h2>
<p>對於普通股東來説，檢查公司內部人士持有多少股票是值得的。通常，內部持股越高，內部人士更有可能被激勵長期發展公司。看起來 Eupraxia Pharmaceuticals 的內部人士擁有公司 18% 的股份，價值約 CA$7000 萬。我們確實在其他地方看到過更高的內部持股水平，但這些持股足以表明內部人士與其他股東之間的利益一致。</p>
<h2>Eupraxia Pharmaceuticals 的內部交易可能告訴我們什麼？</h2>
<p>看到最近的購買是件好事。對過去一年交易的分析也給了我們信心。但另一方面，公司在過去一年中虧損，這讓我們有些謹慎。考慮到內部人士也擁有相當多的 Eupraxia Pharmaceuticals 股票，我們認為他們可能對光明的未來相當有信心。除了瞭解內部交易外，識別 Eupraxia Pharmaceuticals 面臨的風險也是有益的。例如，Eupraxia Pharmaceuticals 有 <strong>3 個警告信號</strong>（其中 2 個不容忽視），我們認為您應該瞭解。</p>
<p>如果您更願意查看另一家公司——一家財務狀況可能更優越的公司——那麼不要錯過這份 <strong>免費</strong> 的有趣公司名單，這些公司具有高股本回報率和低債務。</p>
<p><em>在本文中，內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。</em></p>

EPRX

<p>Eupraxia Pharmaceuticals 的獨立董事 Joseph Freedman 額外購買了 13% 的股份，投資金額為 180 萬加元，平均價格為 7.64 加元。這是過去一年中最大的內部人士購買，表明對公司未來的樂觀態度。儘管去年出現虧損，但內部人士持有公司 18% 的股份，表明與股東利益的一致性。在過去一年中沒有發生內部人士出售，進一步增強了對公司前景的信心，儘管由於存在警示信號，仍需保持謹慎</p>

<p>Those following along with <strong>Eupraxia Pharmaceuticals Inc.</strong> (TSE:EPRX) will no doubt be intrigued by the recent purchase of shares by Joseph Freedman, Independent Director of the company, who spent a stonking CA$1.8m on stock at an average price of CA$7.64. Not only is that a big swing, but it increased their holding size by 13%, which is definitely great to see.</p>
<div class="lb-trans"><p>關注 <strong>Eupraxia Pharmaceuticals Inc.</strong> (TSE:EPRX) 的人無疑會對公司獨立董事 Joseph Freedman 最近購買股票的消息感到好奇，他以平均每股 CA$7.64 的價格花費了高達 CA$1.8 百萬購買股票。這不僅是一個巨大的舉動，還使他們的持股增加了 13%，這無疑是令人欣慰的。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><h2>The Last 12 Months Of Insider Transactions At Eupraxia Pharmaceuticals</h2>
<div class="lb-trans"><h2>Eupraxia Pharmaceuticals 最近 12 個月的內部交易</h2>
</div><p>In fact, the recent purchase by Joseph Freedman was the biggest purchase of Eupraxia Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is CA$7.99. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Eupraxia Pharmaceuticals insiders decided to buy shares at close to current prices.</p>
<div class="lb-trans"><p>事實上，根據我們的記錄，Joseph Freedman 最近的購買是過去 12 個月內內部人士對 Eupraxia Pharmaceuticals 股票的最大購買。因此，很明顯，有內部人士希望在當前價格（CA$7.99 左右）附近進行購買。當然，他們可能改變了主意。但這表明他們持樂觀態度。我們總是喜歡看到內部人士的購買，但值得注意的是，如果這些購買是在遠低於今天的股價時進行的，因為隨着價格上漲，價值折扣可能已經縮小。令人欣慰的是，Eupraxia Pharmaceuticals 的內部人士決定在接近當前價格時購買股票。</p>
</div><p>While Eupraxia Pharmaceuticals insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!</p>
<div class="lb-trans"><p>雖然 Eupraxia Pharmaceuticals 的內部人士在過去一年中購買了股票，但他們並沒有出售。您可以在下面的圖表中看到過去一年內（公司和個人）的內部交易。如果您想確切知道是誰出售的、出售了多少以及何時出售，只需點擊下面的圖表！</p>
</div><p>See our latest analysis for Eupraxia Pharmaceuticals</p>
<div class="lb-trans"><p>查看我們對 Eupraxia Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331" alt="" original-src="https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331"/></p>
<p>TSX:EPRX Insider Trading Volume September 28th 2025</p>
<div class="lb-trans"><p>TSX:EPRX 內部交易量 2025 年 9 月 28 日</p>
</div><p>There are plenty of other companies that have insiders buying up shares. You probably do <strong>not</strong> want to miss this <strong>free</strong> list of undervalued small cap companies that insiders are buying.</p>
<div class="lb-trans"><p>還有很多其他公司也有內部人士購買股票。您可能不想錯過這份 <strong>免費</strong> 的被低估小型公司的名單，內部人士正在購買。</p>
</div><h2>Insider Ownership</h2>
<div class="lb-trans"><h2>內部持股</h2>
</div><p>For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Eupraxia Pharmaceuticals insiders own 18% of the company, worth about CA$70m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.</p>
<div class="lb-trans"><p>對於普通股東來説，檢查公司內部人士持有多少股票是值得的。通常，內部持股越高，內部人士更有可能被激勵長期發展公司。看起來 Eupraxia Pharmaceuticals 的內部人士擁有公司 18% 的股份，價值約 CA$7000 萬。我們確實在其他地方看到過更高的內部持股水平，但這些持股足以表明內部人士與其他股東之間的利益一致。</p>
</div><h2>What Might The Insider Transactions At Eupraxia Pharmaceuticals Tell Us?</h2>
<div class="lb-trans"><h2>Eupraxia Pharmaceuticals 的內部交易可能告訴我們什麼？</h2>
</div><p>It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Eupraxia Pharmaceuticals we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Eupraxia Pharmaceuticals. For example, Eupraxia Pharmaceuticals has <strong>3 warning signs</strong> (and 2 which shouldn't be ignored) we think you should know about.</p>
<div class="lb-trans"><p>看到最近的購買是件好事。對過去一年交易的分析也給了我們信心。但另一方面，公司在過去一年中虧損，這讓我們有些謹慎。考慮到內部人士也擁有相當多的 Eupraxia Pharmaceuticals 股票，我們認為他們可能對光明的未來相當有信心。除了瞭解內部交易外，識別 Eupraxia Pharmaceuticals 面臨的風險也是有益的。例如，Eupraxia Pharmaceuticals 有 <strong>3 個警告信號</strong>（其中 2 個不容忽視），我們認為您應該瞭解。</p>
</div><p>If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this <strong>free</strong> list of interesting companies, that have HIGH return on equity and low debt.</p>
<div class="lb-trans"><p>如果您更願意查看另一家公司——一家財務狀況可能更優越的公司——那麼不要錯過這份 <strong>免費</strong> 的有趣公司名單，這些公司具有高股本回報率和低債務。</p>
</div><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p>
<div class="lb-trans"><p><em>在本文中，內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。</em></p>
</div>

Eupraxia Pharmaceuticals 的獨立董事 Joseph Freedman 增持了 13% 的股份